Mar 10, 2021 / NTS GMT
Andrew C. Weiss - Idorsia Ltd - Senior VP and Head of IR & Corporate Communications
Thank you, Kai. Good morning, good afternoon, everyone. This is Andrew Weiss, Head of Investor Relations and Corporate Communications here at Idorsia. I welcome you to today's call to discuss the second set of Phase III results for daridorexant in insomnia. In the call with me today are our CEO, Jean-Paul Clozel; and our Global Head of Clinical Development, Guy Braunstein. Both are here to walk you through our presentation and prepared remarks, which will then be followed up with a Q&A session. In that session, Martine Clozel will be able to also take questions.
Next slide, please. I do need to remind everybody that we will be making forward-looking statements. Therefore, you have been properly warned about the risks and opportunities of being invested in Idorsia. Next slide, please. So hence, I have the pleasure to hand over the call now to Guy. Please take over.
Guy Braunstein - Idorsia Ltd - Executive VP & Head of Global Clinical Development
Thank you, Andrew,
Idorsia Ltd - Pre Recorded Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot